Aripiprazole
Description
It has been proposed that aripiprazole’s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism of serotonin 5-HT2A receptors.
ATC Classification
Trade names
Spain
Australia Austria Canada Cyprus France
Australia
Spain
Spain
Cyprus
Austria
United States
Spain
Cyprus
United Kingdom
Spain
Cyprus
Cyprus
Australia
Spain
Cyprus Spain
Product Monographs
2D Molecule Structure
Unique Ingredient Identifier (UNII)
82VFR53I78 - ARIPIPRAZOLE
CAS Registry Number
129722-12-9 - aripiprazole
SNOMED-CT
406784005 - Aripiprazole (substance)